{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:15:05Z","timestamp":1764260105475,"version":"3.37.3"},"reference-count":12,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":71,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Mirtazapine is generally well tolerated in medically ill patients with and without formal psychiatric comorbidity to target sleep, appetite, nausea, and pain. However, there is little data regarding mirtazapine's potential to prolong the corrected QT interval (QTc) in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From a retrospective cohort of patients hospitalized on a variety of medical units for whom a psychiatric consult recommended mirtazapine, electrocardiogram (ECG) data were extracted for ECGs obtained up to 3 days before and 6 days after the initial consult. Descriptive statistics were used to characterize the QTc changes and adverse cardiac outcomes, including incident ventricular tachycardia, torsades de pointes, and sudden cardiac death. Multiple linear regression models were completed to assess the effect of potential confounding variables on QTc changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Complete premirtazapine and postmirtazapine ECG data were available for 61 patients, and the average change in QTc was \u20130.31 ms (SD\u2009=\u200936.62 ms). No incidental adverse cardiac outcomes were found. QTc changes were not significantly affected by patient age and sex, initial and maximum mirtazapine dose, days between ECGs, number of concomitant QTc prolonging medications, Charlson comorbidity scores, and electrolyte abnormalities. Due to incomplete potassium, magnesium, and ionized calcium data, electrolytes were excluded from the final regression model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Despite the limitations of this retrospective study, these data suggest that modest doses of mirtazapine may not significantly affect the QTc in medically ill patients. Retrospective cohorts are more feasibly analyzed, but prospective controlled trials could more systematically assess QTc changes with higher doses of mirtazapine in medical settings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2020.01.030","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T19:48:15Z","timestamp":1578599295000},"page":"30-33","source":"Crossref","is-referenced-by-count":8,"title":["Mirtazapine's effect on the QT interval in medically hospitalized patients"],"prefix":"10.9740","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-2824","authenticated-orcid":false,"given":"Nicholas D.","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-9375","authenticated-orcid":false,"given":"Jonathan G.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-4773","authenticated-orcid":false,"given":"Brian A.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"3","key":"2020060307361605700_i2168-9709-10-1-30-b01","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev"},{"key":"2020060307361605700_i2168-9709-10-1-30-b02","unstructured":"Mirtazapine [package insert]. Morgantown (WV): Mylan Pharmaceuticals I; revised2014Oct."},{"issue":"7","key":"2020060307361605700_i2168-9709-10-1-30-b03","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/PSY.0b013e31814b260d","article-title":"Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine","volume":"69","author":"Honig","year":"2007","journal-title":"Psychosom Med"},{"issue":"4","key":"2020060307361605700_i2168-9709-10-1-30-b04","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.psym.2016.02.012","article-title":"Mirtazapine for symptomatic relief on a psychiatric consultation service: a case series","volume":"57","author":"Allen","year":"2016","journal-title":"Psychosomatics"},{"issue":"9","key":"2020060307361605700_i2168-9709-10-1-30-b05","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/pds.2181","article-title":"Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia","volume":"20","author":"Leonard","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"2020060307361605700_i2168-9709-10-1-30-b06","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"2020060307361605700_i2168-9709-10-1-30-b07","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","author":"Gupta","year":"2007","journal-title":"Am Heart J"},{"issue":"15","key":"2020060307361605700_i2168-9709-10-1-30-b08","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1053\/euhj.2000.2249","article-title":"The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology","volume":"21","author":"Haverkamp","year":"2000","journal-title":"Eur Heart J"},{"issue":"2","key":"2020060307361605700_i2168-9709-10-1-30-b09","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","article-title":"A mechanistic link between an inherited and an acquired cardiac-arrhythmia: Herg encodes the I-Kr potassium channel","volume":"81","author":"Sanguinetti","year":"1995","journal-title":"Cell"},{"issue":"11","key":"2020060307361605700_i2168-9709-10-1-30-b10","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"issue":"2","key":"2020060307361605700_i2168-9709-10-1-30-b11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","article-title":"QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update","volume":"59","author":"Beach","year":"2018","journal-title":"Psychosomatics"},{"issue":"1","key":"2020060307361605700_i2168-9709-10-1-30-b12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/10\/1\/30\/2427581\/mhc_2020_01_030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/10\/1\/30\/2427581\/mhc_2020_01_030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:19:06Z","timestamp":1731687546000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/10\/1\/article-p30.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2020.01.030","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}